Amorfix Test for vCJD achieves 100% specificity on 20,000 blood donations in France

25-Jun-2009 - France

Amorfix Life Sciences announced it has tested 20,000 blood donations in France using its EP-vCJD™ blood screening test as part of a large-scale study to demonstrate the feasibility of routine testing of blood donations for vCJD (variant Creutzfeldt-Jakob disease). At the UK specification of a required sensitivity of 1:100,000 dilution of vCJD brain, the Amorfix test was 100% specific with no false positive samples on repeat testing. According to the company, the test performed five times better than required as it was still 100% specific at a sensitivity of 1:500,000 dilution of vCJD brain. At the maximum sensitivity of 1:1,000,000 dilution of vCJD brain, the test was 99.90% specific which exceeds the 99.85% specificity required by the UK Blood Transfusion Service.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...